MarketWatch Article RatingDSM-Firmenich Confirms Mid-Term Targets Despite Weak Vitamin Market Hitting 2023 Earnings -- Update
- Bias Rating
2% Center
- Reliability
25% ReliablePoor
- Policy Leaning
2% Center
- Politician Portrayal
N/A
Continue For Free
Create your free account to see the in-depth bias analytics and more.
Continue
Continue
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates. Already a member: Log inBias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
49% : The Dutch nutrition, health and beauty company anticipates pro forma adjusted earnings before interest, taxes, depreciation and amortization for 2023 will come in between 1.8 billion and 1.9 billion euros ($1.97 billion-$2.08 billion)--compared with EUR2.275 billion for 2022--given the further deterioration of the vitamin market it saw in the second quarter and expectations that prices will remain low until the end of the year.*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.